Accelerating RNA CTx Development from Bench to Bedside (& Back) for Use in Oncology & Beyond

Time: 2:00 pm
day: Day One


  • Debating optimal pathways to the clinic for RNA CTx and cGMP considerations to assess before embarking on clinical development
  • Assessing the best-in-class ways to measure pharmacokinetic and pharmacodynamic properties of RNA CTx
  • Highlighting unique safety and toxicology considerations for this class of drugs and the types of animal models to accelerate to the clinic